Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

Weight loss drugs have risen in popularity in the recent years, but a disconnect remains between those who need the drugs and ...

Holiday weight gain hits home for many come January. These days, folks making resolutions to slim down and get fit have an ...

There is an undeniable connection between a strong immune system and nutrition. Learn why what you eat matters and other ways ...

Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment ...

Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, ...

Maridebart cafraglutide, a novel injectable GIP receptor antagonist/GLP-1 receptor agonist, reduced body weight by ...

Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second ...

Beyond the influence of new therapies on drug pricing trends, Cowen’s report also accounted for the effects of legislation ...

Imagine reversing a life-altering condition without the use of drugs. One British GP is doing exactly that, and his ...

Madrigal Pharmaceuticals' strong launch is confirmed with impressive sales in Q1 and Q2. Learn why MDGL stock could benefit ...

Obesity is a severe public health problem, contributing significantly to the global non-communicable disease burden, ...